The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 801–900 of 1,004
Quan, Y., Xu, J., Xu, Q., Guo, Z., Ou, R., Shang, H., & Wei, Q. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1254824 · Cited by 16
Fang, M., Liu, Y. M., Huang, C., & Fan, S. (2023) · BioFactors · doi:10.1002/biof.2017 · Cited by 16
Yasamineh, S., Mehrabani, F. J., Derafsh, E., Cosimi, R. D., Forood, A. M. K., Soltani, S., Hadi, M., & Gholizadeh, O. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03798-7 · Cited by 17
Spatial omics: An innovative frontier in aging research
Chen, Y., Yang, S., Yu, K., Zhang, J., Wu, M., Zheng, Y., Zhu, Y., Dai, J., Wang, C., Zhu, X., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102158 · Cited by 17
Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegans
Wu, Y., Chen, Y., Yu, X., Zhang, M., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010443 · Cited by 18
Altered Outer Retinal Structure, Electrophysiology and Visual Perception in Parkinson’s Disease
Tran, K. K. N., Lee, P. Y., Finkelstein, D. I., McKendrick, A. M., Nguyen, B. N., Bui, B. V., & Nguyen, C. T. O. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230293 · Cited by 16
Pan, G., Jiang, Y., Zhang, W., Zhang, X., Wang, L., & Cheng, W. (2024) · Psychoradiology · doi:10.1093/psyrad/kkae002 · Cited by 20
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Hu, L., Wang, W., Chen, X., Bai, G., Ma, L., Yang, X., Shu, Q., & Li, X. (2024) · Brain‐X · doi:10.1002/brx2.52 · Cited by 17
Zhang, X., Jin, Y., Wang, M., Ji, C., Chen, Z., Fan, W., Rainer, T. H., Guan, Q., & Li, Q. (2024) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-024-01364-3 · Cited by 16
Yang, Y., Wu, S., Zhao, C., He, H., Wu, Z., Zhang, J., & Song, R. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c08950 · Cited by 16
Liu, S., Yang, S., Feng, K., Wang, C., & Wang, L. (2024) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2024.3418846 · Cited by 17
Role of Lipids in the Pathogenesis of Parkinson’s Disease
Kamano, S., Ozawa, D., Ikenaka, K., & Nagai, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168935 · Cited by 15
Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases
Issa, S. S., Fayoud, H. J., Shaimardanova, A. A., Sufianov, A. A., Суфианова, Г. З., Solovyeva, V. V., & Rizvanov, A. A. (2024) · Biomedicines · doi:10.3390/biomedicines12081906 · Cited by 17
Cao, H., Tian, Q., Chu, L., Wu, L., Gao, H., & Gao, Q. (2024) · Food & Function · doi:10.1039/d4fo01878h · Cited by 16
Sha, M., & Rahamathulla, M. P. (2024) · Quantum Information Processing · doi:10.1007/s11128-024-04588-3 · Cited by 16
Dong, N., Yang, R., Li, X., Zhu, B., Zhao, Z., Cao, J., Wang, J., Lin, X., Zhou, L., & Su, B. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137037 · Cited by 16
Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates
van den Berg, K. R. E., Johansson, M. E., Dirkx, M. F., Bloem, B. R., & Helmich, R. C. G. (2024) · Movement Disorders · doi:10.1002/mds.30081 · Cited by 16
Self-citationNeuroprotective role and mechanistic insights of DJ-1 dimerization in Parkinson’s disease
Lv, L., Zhang, H., Tan, J., & Wang, C. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02136-9 · Cited by 16
A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice
Kauppila, L. A., Holter, S. E. M. T., van de Warrenburg, B. P. C., & Bloem, B. R. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223392 · Cited by 17
Self-citationTargeting immunoproteasome in neurodegeneration: A glance to the future
Tundo, G. R., Cascio, P., Milardi, D., Santoro, A. M., Graziani, G., Lacal, P. M., Bocedi, A., Oddone, F., Parravano, M., Coletta, A., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108329 · Cited by 19
TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
He, X., Xie, Y., Zheng, Q., Zhang, Z., Ma, S., Li, J., Li, M., & Huang, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761773 · Cited by 16
Zifman, N., Levy-Lamdan, O., Hiller, T., Thaler, A., Dolev, I., Mirelman, A., Fogel, H., Hallett, M., & Maidan, I. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00793-0 · Cited by 15
Fang, M., Luo, L., Chen, Y., Liu, Y. M., Yan, Y., Wang, F., Zou, Y., Zhu, H., Wu, X., Jin, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202412152 · Cited by 15
Jiao, J., Liu, W., Gao, G., & Yang, H. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1538166 · Cited by 15
From RIPK1 to Necroptosis: Pathogenic Mechanisms in Neurodegenerative Diseases
Kang, A., Qiao, Y., Pan, S., Yan, F., Chen, H., & Bai, Y. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04448-1 · Cited by 17
Clinical Investigation of Tyrosinase Inhibitors: Past, Present, and Future
Wang, Y. Y., Jiang, R., Xiong, B., Zhu, J., Sang, J., Li, H., Chen, C., Xu, Z., Zhang, W., Chen, Y., et al. (2025) · Drug Development Research · doi:10.1002/ddr.70113 · Cited by 19
Interpretable Early Detection of Parkinson’s Disease Through Speech Analysis
Simone, L., Camporeale, M. G., Rubino, V. M., Gervasi, V., & Dimauro, G. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-95841-0_69 · Cited by 15
Zhou, S., Xiong, X., Hou, J., Duan, Q., Zheng, Y., Jiang, T., Huang, J., He, H., Xu, J., Chen, K., et al. (2025) · Advanced Science · doi:10.1002/advs.202408503 · Cited by 15
Motor symptoms of Parkinson’s disease: critical markers for early AI-assisted diagnosis
Yang, N., Liu, J., Sun, D., Ding, J., Sun, L., Qi, X., & Yan, W. Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1602426 · Cited by 15
Xu, J., Guo, C., Zhou, G., Chen, H., Dai, P., Tang, C., Lin, S., Chen, T., Zhang, C., Chen, F., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123614 · Cited by 15
Anti-inflammatory effect of curcumin on neurological disorders: a narrative review
Zhou, B., & Hu, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1658115 · Cited by 19
Ma, Y., Yang, C., Liang, Q., He, Z., Weng, W., Lei, J., Skudder‐Hill, L., Jiang, J., & Feng, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02815-5 · Cited by 15
Berdowska, I., Matusiewicz, M., & Krzystek‐Korpacka, M. (2022) · Antioxidants · doi:10.3390/antiox11030524 · Cited by 14
Pinizzotto, C. C., Patwardhan, A., Aldarondo, D., & Kritzer, M. F. (2022) · Hormones and Behavior · doi:10.1016/j.yhbeh.2022.105206 · Cited by 15
Sex and gender differences in dementia
Salwierz, P., Davenport, C., Sumra, V., Iulita, M. F., Ferretti, M. T., & Tartaglia, M. C. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.07.002 · Cited by 16
Ding, L., Liang, J., Guo, W., Zhang, Y., Wu, X., & Zhang, W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.971528 · Cited by 15
Defective PTEN-induced kinase 1/Parkin mediated mitophagy and neurodegenerative diseases
Braun, M. M., & Puglielli, L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1031153 · Cited by 16
Clinical considerations in Parkinson’s disease cell therapy
Xue, J., Wu, Y., Bao, Y., Zhao, M., Li, F., Sun, J., Sun, Y., Wang, J., Chen, L., Mao, Y. Q., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101792 · Cited by 16
The Role of Cannabinoid Type 2 Receptors in Parkinson’s Disease
Basile, M. S., & Mazzon, E. (2022) · Biomedicines · doi:10.3390/biomedicines10112986 · Cited by 17
Warnecke, T., Lummer, C., Rey, J. W., Claus, I., & Lüttje, D. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01444-3 · Cited by 15
Endoplasmic Reticulum Stress-Regulated Chaperones as a Serum Biomarker Panel for Parkinson’s Disease
Mnich, K., Moghaddam, S., Browne, P. J., Counihan, T. J., Fitzgerald, S. P., Martin, K., Richardson, C., Afshin Samali, A., & Gorman, A. M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03139-0 · Cited by 15
Altered Neurovascular Coupling for Multidisciplinary Intensive Rehabilitation in Parkinson's Disease
Li, T., Wang, L., Piao, Z., Chen, K., Yu, X. X., Wen, Q., Suo, D., Zhang, C., Funahashi, S., Pei, G., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1204-22.2023 · Cited by 15
The Potential Regulation of A-to-I RNA Editing on Genes in Parkinson’s Disease
Wu, S., Xue, Q., Qin, X., Wu, X., Kim, P., Chyr, J., Zhou, X., & Huang, L. (2023) · Genes · doi:10.3390/genes14040919 · Cited by 15
Wang, L., Zhou, C., Zhang, W., Zhang, M., Cheng, W., & Feng, J. (2023) · Neurology · doi:10.1212/wnl.0000000000207408 · Cited by 15
The Impact of microRNAs on Mitochondrial Function and Immunity: Relevance to Parkinson’s Disease
Guedes, B. F. S., Cardoso, S. M., & Esteves, A. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051349 · Cited by 16
Biosensors for α-synuclein detection: Towards an improved diagnosis of Parkinson's disease
Carneiro, P., Morais, S., & Pereira, M. D. C. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117150 · Cited by 16
Leucine-rich repeat kinase 2 at a glance
Zhu, C., Herbst, S., & Lewis, P. A. (2023) · Journal of Cell Science · doi:10.1242/jcs.259724 · Cited by 17
Neuroprotection of phytic acid in Parkinson’s and Alzheimer’s disease
Chen, Y., Yuan, W., Xu, Q., & Reddy, M. B. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105856 · Cited by 16
Wu, C., Wu, H., Zhou, C., Guan, X., Guo, T., Cao, Z., Wu, J., Liu, X., Chen, J., Wen, J., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.16108 · Cited by 16
Hasani, M., & Ghods, M. (2023) · Molecular Physics · doi:10.1080/00268976.2023.2270082 · Cited by 15
miR‐221 and Parkinson's disease: A biomarker with therapeutic potential
Zamanian, M. Y., Ivraghi, M. S., Gupta, R., Prasad, K., Alsaab, H. O., Hussien, B. M., Ahmed, H., Ramadan, M. F., Golmohammadi, M., Nikbakht, N., et al. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16207 · Cited by 15
Neutrophil extracellular traps in central nervous system (CNS) diseases
Shao, B., Jiang, J., Zhao, Y.-C., Zheng, X.-R., Xi, N., Zhao, G.-R., Huang, X., & Wang, S. (2024) · PeerJ · doi:10.7717/peerj.16465 · Cited by 15
Wu, C., Wu, H., Zhou, C., Guan, X., Guo, T., Wu, J., Chen, J., Wen, J., Qin, J., Tan, S., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106406 · Cited by 15
Sabherwal, G., & Kaur, A. (2024) · Multimedia Tools and Applications · doi:10.1007/s11042-024-18398-3 · Cited by 15
An artificial protein modulator reprogramming neuronal protein functions
Lin, P., Zhang, B., Yang, H., Yang, S., Xue, P., Chen, Y., Yu, S., Zhang, J., Zhang, Y., Chen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46308-6 · Cited by 15
Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium
Daniels, C., Rodríguez-Antigüedad, J., Jentschke, E., Kulisevsky, J., & Volkmann, J. (2024) · Neurological Research and Practice · doi:10.1186/s42466-024-00309-4 · Cited by 15
Kim, K., Jang, A., Shin, H., Ye, I., Lee, J., Kim, T., Park, H., & Hong, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00520 · Cited by 15
Actin-nucleation promoting factor N-WASP influences alpha-synuclein condensates and pathology
Jackson, J., Hoffmann, C., Scifo, E., Wang, H., Wischhof, L., Piazzesi, A., Mondal, M., Shields, H., Zhou, X., Mondin, M., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06686-7 · Cited by 14
Zhang, Y., Jiang, Y., Yu, Z., Li, Y., Lin, X., Weng, Y., Guo, Z., Hu, H., Shao, W., Yu, G., et al. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.134559 · Cited by 15
Neurological symptoms in adults with Gaucher disease: a systematic review
Imbalzano, G., Ledda, C., Romagnolo, A., Covolo, A., Lopiano, L., & Artusi, C. A. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12439-5 · Cited by 15
Kim, H., Park, C., Kim, J., Jang, S., & Lee, H. K. (2024) · IEEE Access · doi:10.1109/access.2024.3405009 · Cited by 17
Xu, Q., Chen, Y., Chen, D., & Reddy, M. B. (2024) · Nutrition and Metabolic Insights · doi:10.1177/11786388241253436 · Cited by 15
Giraldo-Berrio, D., Mendivil‐Perez, M., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2024) · Neurotoxicity Research · doi:10.1007/s12640-024-00705-3 · Cited by 15
The pathogenesis of Parkinson’s disease and crosstalk with other diseases
Liu, T., GUO, D., & Wei, J. (2024) · Biocell · doi:10.32604/biocell.2024.051518 · Cited by 15
Gorji, A., & Jouzdani, A. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304355 · Cited by 19
Liu, Y., Li, H., Yang, M., Guo, J., Sun, Z., Wang, S., Li, R., Pang, X., Kim, Y., Wang, X., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070972 · Cited by 17
Park, J., Kim, J., Park, H., Kim, T., & Lee, S. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2380294 · Cited by 18
Assessment of CRISPRa-mediated gdnf overexpression in an In vitro Parkinson’s disease model
Guzmán-Sastoque, P., Sotelo, S., Esmeral, N. P., Albarracín, S. L., Sutachan, J. J., Reyes, L. H., Muñoz-Camargo, C., Cruz, J. C., & Bloch, N. I. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1420183 · Cited by 15
Liang, K., Li, Y., Kang, J., Liu, B., Zhang, D., Wang, L., Wang, W. J., & Wang, Q. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100963 · Cited by 15
The roles of TAF1 in neuroscience and beyond
Crombie, E. M., Cleverley, K., Timmers, H. T. M., & Fisher, E. (2024) · Royal Society Open Science · doi:10.1098/rsos.240790 · Cited by 15
Hypoxia-inducible factor-1 as targets for neuroprotection : from ferroptosis to Parkinson’s disease
Wang, C., Lv, S., Zhao, H., He, G., Liang, H., Chen, K., Qu, M., He, Y., & Ou, C. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07832-x · Cited by 18
Ge, Y., Zhao, W., Zhang, L., Zhao, X., Shu, X., Li, J., Qiao, L., Liu, Y., & Wang, H. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-05529-6 · Cited by 15
Gong, X., Tan, Z., Xu, H., Jiang, X., & Chen, L. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500824 · Cited by 17
Razavi, S. M., Esmaealzadeh, N., Ataei, M., Afshari, N., Saleh, M., Amini, Y., Hasrati, S., Hashemi, F. G., Mortazavi, A., Shalmani, L. M., et al. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01542-9 · Cited by 15
Dream Content Predicts Motor and Cognitive Decline in Parkinson's Disease
Otaiku, A. I. (2021) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13318 · Cited by 15
Association Between Metabolic Syndrome and Mild Parkinsonian Signs Progression in the Elderly
Peng, Z., Zhou, R., Liu, D., Cui, M., Yu, K., Yang, H., Li, L., Liu, J., Chen, Y., Hong, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.722836 · Cited by 15
Lu, S., Jiang, H., & Shi, Y. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13570 · Cited by 15
Abnormal circadian blood pressure regulation and cognitive impairment in α-synucleinopathies
Tanaka, R., & Hattori, N. (2022) · Hypertension Research · doi:10.1038/s41440-022-01032-w · Cited by 16
Ke, K., Gu, X.-S., Zhang, H., Jiang, Y.-C., Li, J.-R., Yan, J., Wang, X.-J., & Shen, J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355815 · Cited by 15
Lü, M.-H., Wang, Z., Xing, L.-Z., Zhang, W., Han, F., Huang, G., Liu, W., Zhang, Y., Cui, J., & Cui, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115122 · Cited by 16
Spee, B. T. M., de Vries, N. M., Zeggio, S., Plijnaer, M., Koksma, J., Duits, A., Stap, T. B., Pasman, G., Haeyen, S., Darweesh, S. K. L., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-024-12878-0 · Cited by 16
Self-citationCagalinec, M., Mohd, A., Borecká, S., Bultynck, G., Choubey, V., Yanovsky‐Dagan, S., Ezer, S., Gašperíková, D., Harel, T., Jurkovičová, D., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119954 · Cited by 15
Neurotoxic risks of long-term environmental exposure to pesticides: a review
Leng, Y., Zeng, Y., Zhang, Y., Zhang, J., Xin, H., Hou, M., Ma, S., & Zhang, H. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111626 · Cited by 14
Branched-Chain Amino Acids in Parkinson’s Disease: Molecular Mechanisms and Therapeutic Potential
Huang, H.-Y., Tsao, S., & Yeh, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146992 · Cited by 15
Gutowski, T., Stodulska, O., Ćwiklińska, A., Gutowska, K., Kopeć, K., Betka, M. M., Antkiewicz, R., Koziorowski, D., & Szlufik, S. (2025) · Sensors · doi:10.3390/s25164924 · Cited by 14
Receptor-mediated mitophagy: a new target of neurodegenerative diseases
Yang, J., Yang, F., Chen, G., Liu, M., Yuan, S., & Zhang, T. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1665315 · Cited by 16
Lysine lactylation in diseases: beyond histone lactylation
Liu, Y., Guo, X., Hu, X., Zhou, S., Yang, Q. E., Feng, P., & Zeng, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08223-6 · Cited by 17
From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson’s disease
Tu, R., Han, Z., Zhang, H., Jia, X., Sun, T., Liu, H., Li, J., Tang, M., & Wang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1709561 · Cited by 15
Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease
Pan, Y., Xue, J., Chen, J., Zhang, X., Tu, T., Xiao, Q., Huang, W., Liu, Q., Zhu, L., Li, J., et al. (2022) · Movement Disorders · doi:10.1002/mds.29041 · Cited by 14
Xing, N., Dong, Z., Wu, Q., Kan, P., Han, Y., Cheng, X., & Zhang, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948615 · Cited by 14
Avgerinos, K. I., Liu, J., & Dalamaga, Μ. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100233 · Cited by 18
Productivity, Collaboration and Impact of Cuban Scientific Research on Parkinson's Disease in Scopus
Piñera-Castro, H. J., & Cubela, F. J. M. (2022) · Data & Metadata · doi:10.56294/dm20222 · Cited by 14
Cell type- and region-specific translatomes in an MPTP mouse model of Parkinson's disease
Huang, Q., Chen, C., Chen, W., Cai, C., Xing, H., Li, J., Li, M., & Ma, S. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106105 · Cited by 14
PesViT: a deep learning approach for detecting misuse of pesticides on farm
Thảo, L. Q., Thien, N. D., Bach, N. C., Cuong, D. D., Anh, L. D., Khanh, D. G., Hieu, N. H. M., & Minh, N. T. H. (2023) · The Journal of Supercomputing · doi:10.1007/s11227-023-05302-3 · Cited by 14
de Luna, J. R. G., Lima, D. P., Gomes, V. C., de Almeida, S. B., Monteiro, P. A., Júnior, A. B. V., da Silva, T. A. M., Gradvohl, L. B., Bruno, L. B., Marques, M. L. S., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230010 · Cited by 14
He, Z.-Q., Huan, P.-F., Wang, L., & He, J. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04004-9 · Cited by 15
Schootemeijer, S., de Vries, N. M., Macklin, E. A., Roes, K. C. B., Joosten, H., Omberg, L., Ascherio, A., Schwarzschild, M. A., & Bloem, B. R. (2023) · BMC Neurology · doi:10.1186/s12883-023-03355-8 · Cited by 14
Self-citationTang, C., Sun, R., Xue, K., Wang, M., Liang, S., Kambey, P. A., Shi, M., Wu, C., Chen, G., & Gao, D. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14461 · Cited by 14
Awad, P. S., dos Santos, D. T., Santos‐Lobato, B. L., Camargos, S., Cornejo‐Olivas, M., Rieder, C. R. D. M., Mata, I. F., Chaná‐Cuevas, P., Klein, C., & Schuh, A. F. S. (2023) · Movement Disorders · doi:10.1002/mds.29614 · Cited by 14
Self-citationFeng, Z., Zhao, Q., Wu, J., Yang, Y., Jia, X., Ma, J., Tang, H., Yuan, H., Yang, G., & Lu, Y. (2023) · BMC Medicine · doi:10.1186/s12916-023-03122-z · Cited by 14
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
